Catalyst

Slingshot members are tracking this event:

Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY

100%

Additional Information

Additional Relevant Details Higher expression of PD-L1 (programmed death-ligand 1) was associated with higher response rates, however low levels of PD-L1 expression did not preclude response Responses were ongoing in the majority of people Complete Responses (CR) were observed regardless of levels of PD-L1 expression
http://www.roche.com...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 08, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Atezolizumab, Advanced Bladder Cancer, Imvigor 210, Metastatic Urothelial Cancer